What is Amalgam Rx?
Amalgam Rx operates as a pivotal infrastructure provider within the digital therapeutics and chronic care ecosystem. With over 15 years of operational history, the company specializes in the rapid development and scaling of clinically validated digital solutions. Its platform serves as a critical bridge, enabling life sciences organizations to integrate digital health tools into standard clinical workflows. By facilitating the entire product lifecycle—from initial research and development to commercial-scale deployment—Amalgam Rx addresses the complex needs of payers, providers, and patients. The firm's impact is evidenced by the generation of over 5 billion RWE data points, which serve to validate the efficacy of its regulated technologies and demonstrate sustained value in diverse healthcare business models.
How much funding has Amalgam Rx raised?
Amalgam Rx has raised a total of $52.3M across 3 funding rounds:
Series A
$17.4M
Other Financing Round
$27M
Private Equity
$7.9M
Series A (2023): $17.4M with participation from Novo Nordisk
Other Financing Round (2025): $27M led by Catalio Capital Management
Private Equity (2025): $7.9M, investors not publicly disclosed
Key Investors in Amalgam Rx
Catalio Capital Management
Catalio Capital Management is a New York-based investment firm specializing in innovative healthcare investing across private, public, and credit markets. The firm focuses on breakthrough biomedical technology companies and leverages a network of venture partners to provide expert insights.
Novo Nordisk
Novo Nordisk is a global pharmaceutical company focused on developing innovative medicines and drug delivery systems for the treatment of serious chronic diseases. They specialize in biological medicines for diabetes, obesity, and rare blood and endocrine disorders.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Amalgam Rx?
With the successful closure of this recent financing, Amalgam Rx is well-positioned to accelerate its enterprise-level initiatives. The strategic capital will likely be deployed to enhance its RWE data analytics capabilities and expand its footprint in international markets where chronic care management remains a high-priority challenge. As the company continues to refine its end-to-end methodology, it is expected to deepen its partnerships with global life sciences entities, further integrating its digital solutions into the standard of care. The focus remains on scaling its regulated, clinically validated technologies to reduce systemic costs while improving patient outcomes, ensuring that Amalgam Rx remains a dominant force in the evolving digital health landscape.
See full Amalgam Rx company page
